Tower Research Capital (TRC)’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-13,921
| Closed | -$7.54K | – | 5581 |
|
|
2025
Q2 | $7.54K | Buy |
13,921
+5,805
| +72% | +$3.45K | ﹤0.01% | 4049 |
|
|
2025
Q1 | $5.32K | Sell |
8,116
-12,025
| -60% | -$12.7K | ﹤0.01% | 4130 |
|
|
2024
Q4 | $20.5K | Buy |
+20,141
| New | +$36.8K | ﹤0.01% | 3161 |
|
|
2024
Q3 | – | Sell |
-57,721
| Closed | -$20.7K | – | 5953 |
|
|
2024
Q2 | $20.7K | Buy |
57,721
+41,797
| +262% | +$22.6K | ﹤0.01% | 3749 |
|
|
2024
Q1 | $10.7K | Sell |
15,924
-4,874
| -23% | -$3.54K | ﹤0.01% | 3669 |
|
|
2023
Q4 | $11.3K | Buy |
20,798
+7,377
| +55% | +$3.4K | ﹤0.01% | 4142 |
|
|
2023
Q3 | $8.05K | Sell |
13,421
-58,764
| -81% | -$62.9K | ﹤0.01% | 4400 |
|
|
2023
Q2 | $93.8K | Buy |
72,185
+63,712
| +752% | +$87K | ﹤0.01% | 2065 |
|
|
2023
Q1 | $15K | Buy |
8,473
+3,234
| +62% | +$9.23K | ﹤0.01% | 3810 |
|
|
2022
Q4 | $17K | Sell |
5,239
-29,175
| -85% | -$113K | ﹤0.01% | 3290 |
|
|
2022
Q3 | $169K | Buy |
34,414
+2,662
| +8% | +$13.7K | ﹤0.01% | 2088 |
|
|
2022
Q2 | $131K | Sell |
31,752
-906
| -3% | -$3.92K | ﹤0.01% | 2085 |
|
|
2022
Q1 | $189K | Buy |
32,658
+3,262
| +11% | +$19.4K | ﹤0.01% | 1775 |
|
|
2021
Q4 | $221K | Sell |
29,396
-4,446
| -13% | -$38.6K | ﹤0.01% | 1694 |
|
|
2021
Q3 | $305K | Buy |
33,842
+26,278
| +347% | +$260K | 0.01% | 1385 |
|
|
2021
Q2 | $91K | Sell |
7,564
-151
| -2% | -$1.71K | ﹤0.01% | 2508 |
|
|
2021
Q1 | $96K | Buy |
7,715
+4,205
| +120% | +$56.7K | ﹤0.01% | 2621 |
|
|
2020
Q4 | $55K | Sell |
3,510
-9,839
| -74% | -$115K | ﹤0.01% | 3029 |
|
|
2020
Q3 | $126K | Sell |
13,349
-13,070
| -49% | -$141K | ﹤0.01% | 2959 |
|
|
2020
Q2 | $237K | Buy |
26,419
+26,219
| +13,110% | +$243K | 0.01% | 1644 |
|
|
2020
Q1 | $1K | Sell |
200
-17,051
| -99% | -$127K | ﹤0.01% | 2835 |
|
|
2019
Q4 | $144K | Buy |
17,251
+6,081
| +54% | +$55.9K | 0.01% | 754 |
|
|
2019
Q3 | $101K | Buy |
11,170
+10,521
| +1,621% | +$118K | 0.01% | 1339 |
|
|
2019
Q2 | $7K | Buy |
649
+388
| +149% | +$4.13K | ﹤0.01% | 2788 |
|
|
2019
Q1 | $2K | Buy |
+261
| New | +$2.67K | ﹤0.01% | 3452 |
|
|
2018
Q4 | – | Sell |
-1,166
| Closed | -$20K | – | 4299 |
|
|
2018
Q3 | $20K | Buy |
1,166
+99
| +9% | +$1.5K | ﹤0.01% | 2353 |
|
|
2018
Q2 | $15K | Sell |
1,067
-13,333
| -93% | -$221K | ﹤0.01% | 2598 |
|
|
2018
Q1 | $274K | Buy |
14,400
+13,568
| +1,631% | +$290K | 0.02% | 735 |
|
|
2017
Q4 | $14K | Sell |
832
-1,719
| -67% | -$25.6K | ﹤0.01% | 2337 |
|
|
2017
Q3 | $38K | Buy |
2,551
+346
| +16% | +$3.83K | ﹤0.01% | 2228 |
|
|
2017
Q2 | $19K | Buy |
+2,205
| New | +$14.1K | ﹤0.01% | 1242 |
|
|
2016
Q2 | – | Sell |
-400
| Closed | -$2K | – | 4911 |
|
|
2016
Q1 | $2K | Buy |
+400
| New | +$2.4K | ﹤0.01% | 3435 |
|
|
2015
Q4 | – | Sell |
-47,836
| Closed | -$270K | – | 4994 |
|
|
2015
Q3 | $270K | Buy |
47,836
+44,628
| +1,391% | +$368K | 0.03% | 234 |
|
|
2015
Q2 | $36K | Sell |
3,208
-2,549
| -44% | -$32.9K | ﹤0.01% | 1622 |
|
|
2015
Q1 | $90K | Buy |
+5,757
| New | +$89.1K | 0.01% | 980 |
|
|
2014
Q4 | – | Sell |
-425
| Closed | -$5K | – | 4626 |
|
|
2014
Q3 | $5K | Buy |
425
+325
| +325% | +$4.25K | ﹤0.01% | 3314 |
|
|
2014
Q2 | $2K | Buy |
+100
| New | +$1.44K | ﹤0.01% | 3453 |
|
|
2014
Q1 | – | Sell |
-6
| Closed | – | – | 4863 |
|
|
2013
Q4 | $0 | Sell |
6
-1,535
| -100% | -$17.7K | ﹤0.01% | 4877 |
|
|
2013
Q3 | $16K | Buy |
1,541
+1,259
| +446% | +$12.5K | ﹤0.01% | 2876 |
|
|
2013
Q2 | $2K | Buy |
+282
| New | +$2.46K | ﹤0.01% | 3509 |
|
Other funds holding SGMO
GCP
Tower Research Capital (TRC)'s SGMO Position: Q3 2025 in Review
Tower Research Capital (TRC) sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2025, closing a stake of 13,921 shares — an estimated $7.54K sold.
Tower Research Capital (TRC) first reported a position in SGMO in Q2 2013 and held it in 40 quarters. The position peaked at $305K in Q3 2021. 112 funds tracked by Wall St. Rank hold SGMO as of Q3 2025.
- Tower Research Capital (TRC) reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 13,921 SANGAMO THERAPEUTICS INC shares in Q3 2025, an estimated $7.54K.
- Tower Research Capital (TRC) first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 40 quarters.
- Tower Research Capital (TRC)'s SANGAMO THERAPEUTICS INC position peaked at $305K in Q3 2021.
- 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.